Ayna Duran, Gizem

Profile Picture
Profile URL
https://hdl.handle.net/20.500.14365/7475
Name Variants
Ayna Duran, Assist. Prof. Dr. Gizem
Ayna, Duran, G.
Duran, Gizem Ayna
Gizem Ayna Duran
Job Title
Email Address
gizem.duran@ieu.edu.tr
aynadurangizem@gmail.com
Main Affiliation
05.02. Biomedical Engineering
Status
Current Staff
Website
ORCID ID
0000-0002-2168-753X
Scopus Author ID
37010637600
Turkish CoHE Profile ID
CF27DBF6963C420B
Google Scholar ID
oxOjc_4AAAAJ
WoS Researcher ID
JOZ-2509-2023
Files
1 gizem.png (605.75 KB)

Sustainable Development Goals

NO POVERTY1
NO POVERTY
0
Research Products
ZERO HUNGER2
ZERO HUNGER
0
Research Products
GOOD HEALTH AND WELL-BEING3
GOOD HEALTH AND WELL-BEING
18
Research Products
QUALITY EDUCATION4
QUALITY EDUCATION
0
Research Products
GENDER EQUALITY5
GENDER EQUALITY
0
Research Products
CLEAN WATER AND SANITATION6
CLEAN WATER AND SANITATION
0
Research Products
AFFORDABLE AND CLEAN ENERGY7
AFFORDABLE AND CLEAN ENERGY
0
Research Products
DECENT WORK AND ECONOMIC GROWTH8
DECENT WORK AND ECONOMIC GROWTH
0
Research Products
INDUSTRY, INNOVATION AND INFRASTRUCTURE9
INDUSTRY, INNOVATION AND INFRASTRUCTURE
0
Research Products
REDUCED INEQUALITIES10
REDUCED INEQUALITIES
0
Research Products
SUSTAINABLE CITIES AND COMMUNITIES11
SUSTAINABLE CITIES AND COMMUNITIES
0
Research Products
RESPONSIBLE CONSUMPTION AND PRODUCTION12
RESPONSIBLE CONSUMPTION AND PRODUCTION
0
Research Products
CLIMATE ACTION13
CLIMATE ACTION
0
Research Products
LIFE BELOW WATER14
LIFE BELOW WATER
0
Research Products
LIFE ON LAND15
LIFE ON LAND
0
Research Products
PEACE, JUSTICE AND STRONG INSTITUTIONS16
PEACE, JUSTICE AND STRONG INSTITUTIONS
0
Research Products
PARTNERSHIPS FOR THE GOALS17
PARTNERSHIPS FOR THE GOALS
0
Research Products
Documents

10

Citations

177

h-index

2

Go to Scopus profile
Documents

10

Citations

46

Go to WoS profile
Scholarly Output

23

Articles

11

Views / Downloads

127/256

Supervised MSc Theses

1

Supervised PhD Theses

0

WoS Citation Count

2

Scopus Citation Count

2

Patents

0

Projects

1

WoS Citations per Publication

0.09

Scopus Citations per Publication

0.09

Open Access Source

17

Supervised Theses

1

JournalCount
Analytical Biochemistry1
Asian Biomedicine1
Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi1
Discover Oncology1
European Journal of Biology1
Current Page: 1 / 3

Scopus Quartile Distribution

Competency Cloud

GCRIS Competency Cloud

Filters

2020 - 202523
Reset filters

Settings

Scholarly Output Search Results

Now showing 1 - 10 of 23
  • Thumbnail Image
    Article
    Determination of Eight Hub Genes and Functional Pathways Affecting Both the Survival of Early- and Late-Stage Colon Cancer Patients
    (Kare Publ, 2023) Ayna Duran, Gizem; Sert, Fatma; Duran, Assist. Prof. Dr. Gizem Ayna; Duran, Gizem Ayna
    OBJECTIVEThe stage of colon cancer (CC) and therefore the level at which the treatment is initiated affects the survival of CC patients. In our study, we aimed to identify the common survival-related genes in both early-and late-stage CC patients.METHODSInformation on the demographic characteristics of 581 patients and microarray expression profiles (GSE39582) were obtained from the gene expression omnibus database. Survival analysis was per-formed using univariate and multivariate Cox regression methods with the help of R3.53 programming language and Kaplan-Meier graphics through the R software Survival package. ShinyGO v0.741 gene ontology enrichment analysis was performed to clarify the common and functional pathways related to both early-and late-stage CC cancer patients' data.RESULTSCox regression analysis indicated that overall survival and relapse-free survival of CC patients were strongly influenced by stage. Genes that significantly affect prognosis and survival in early-and late -stage CC patients were identified. As a result of gene enrichment analysis, arginine binding, oxidore-ductase activity, and methylcytosine dioxygenase activity and related eight hub genes (TM4SF5, NOS3, Ten eleven translocation [TET1], TET3, JMJD7, AKR1C1, prenylcysteine oxidase 1 like, Methionine sulfoxide reductase A) were identified.CONCLUSIONAccording to our results, it might be considered that developing new treatment strategies based on eight hub-genes related to arginine binding, oxidoreductase activity, and methylcytosine dioxygenase activity detected at different stages of CC might increase the success of targeted therapies.
  • Thumbnail Image
    Book Part
  • Thumbnail Image
    Article
    Upregulated Acute Systemic Inflammation-Related Genes Based on Endotoxin Exposure Provide ‘Survival Benefit’ or Create ‘High Risk of Death’ in Leukaemia and Colon Cancer
    (Istanbul University, 2024-07-10) Duran, Gizem Ayna; Duran, Assist. Prof. Dr. Gizem Ayna; Ayna Duran, Gizem
    Objective: Although endotoxin exposure has been shown to trigger innate immune responses and promote cancer, it has also been shown to prevent cancer formation. In our study, survival analysis was performed to determine whether the upregulated genes triggered by endotoxins have hazardous effects on cancers or provide a survival benefit. Materials and Methods: Gene intensity values of control and bacterial endotoxin-administered individuals were obtained from the Gene Expression Omnibus database. Using the R "Linear Models for Microarray Data" package, differentially expressed gene analyses were conducted to determine genes that differ between healthy and bacterial endotoxin-administered samples. "ShinyGo 0.80" web-based tool was used to determine the disease types indicated by these genes. The "Kaplan-Meier Plotter" web-based tool was used to conduct survival analysis. Results: Genes that create an innate immune response to bacterial endotoxin exposure and are upregulated differently than in individuals without exposure were identified. According to gene enrichment analyses, the two main types of cancer identified were leukaemia/lymoma and colon cancer. We detected that MLF1, STAT5B, and BCL3 genes led to poor survival; however, the ARHGAP26 gene was protective for acute myeloid leukaemia patients. In the case of colon cancer, SMAD7 and TLR2 genes were determined as leading to "high risk of death". Conclusion: Once the systemic inflammation-related genes identified in our study are confirmed through laboratory experiments in samples taken from solid tissue in the case of colon cancer and at the level of genes obtained from blood samples in leukemias, genetically targeted treatments will also be possible.
  • Thumbnail Image
    Book Part
  • Thumbnail Image
    Book Part
  • Thumbnail Image
    Article
    Autophagy-Related Genes Affect the Survival of Multiple Myeloma Patients Depending on Chromosomal Abnormality
    (Walter De Gruyter Gmbh, 2022-10-01) Ayna Duran, Gizem; Benderli Cihan, Yasemin
    Background: Targeting autophagy at gene level may be promising in multiple myeloma (MM) treatment depending on chromosomal abnormality (ABN) status.Objectives: We aimed to investigate the role of ABN on survival of MM patients and to identify prognosis related autophagy-related genes (ARGs) for patients with or without ABN.Methods: Gene intensity values of 222 ARG for 548 MM patients were obtained from the Affymetrix Human Genome U133 Plus 2.0 Array (GPL570) platform containing 54,675 probes (GSE24080). A dataset containing data from 1576 MM patients with 1q21 amplification (GSE4204, GSE4452, GSE4581, and GSE2658) was used for validation. Survival analysis of the patients was analyzed using univariate and multivariate Cox regression method with the help of R3.53 programming language and Kaplan-Meier graphics were created. The Gene Ontology enRIchmentanaLysis and visuaLizAtion (GOrilla) tool was used to define the related biological processes and pathways.Results: The overall survival (OS) and event-free survival (EFS) in all MM patients were strongly influenced by ABN. In the group of patients with ABN, 41 ARGs were found to be important in prognosis, whereas in the group of patients without ABN, 13 ARGs were found to be important in prognosis. CDKN1A, FKBP1B, FOXO3, and NCKAP1 ARGs were commonly significant in both groups and found to be survival triggering.Conclusions: The classification of MM patients according to the absence or presence of ABN is important in the determination of survival status. Detection of survival related ARGs in patients with chromosomal anomalies may be a new therapeutic target in treatment.
  • Thumbnail Image
    Article
    Citation - WoS: 2
    Citation - Scopus: 2
    Identification of Potential Inhibitors for Drug Resistance in Acute Lymphoblastic Leukemia Through Differentially Expressed Gene Analysis and in Silico Screening
    (Academic press inc elsevier science, 2024-11) Özay, Başak; Tükel, Ezgi Yağmur; Ayna Duran, Gizem; Kiraz, Yağmur; Duran, Gizem Ayna
    Acute lymphoblastic leukemia (ALL) is a disease of lymphocyte origin predominantly diagnosed in children. While its 5-year survival rate is high, resistance to chemotherapy drugs is still an obstacle. Our aim is to determine differentially expressed genes (DEGs) related to Asparaginase, Daunorubicin, Prednisolone, and Vincristine resistance and identify potential inhibitors via docking. Three datasets were accessed from the Gene Expression Omnibus database; GSE635, GSE19143, and GSE22529. The microarray data waes analyzed using R4.2.0 and Bioconductor packages, and pathway and protein-protein interaction analysis were performed. We identified 1294 upregulated DEGs, with 12 genes consistently upregulated in all four resistant groups. KEGG analysis revealed an association with the PI3K-Akt pathway. Among DEGs, 33 hub genes including MDM2 and USP7 were pinpointed. Within common genes, CLDN9 and HS3ST3A1 were subjected to molecular docking against 3556 molecules. Following ADMET analysis, three drugs emerged as potential inhibitors: Flunarizine, Talniflumate, and Eltrombopag. Molecular dynamics analysis for HS3ST3A1 indicated all candidates had the potential to overcome drug resistance, Eltrombopag displaying particularly promising results. This study promotes a further understanding of drug resistance in ALL, introducing novel genes for consideration in diagnostic screening. It also presents potential inhibitor candidates to tackle drug resistance through repurposing.
  • Thumbnail Image
    Article
    Bioinformatics Based Drug Repurposing Approach for Breast and Gynecological Cancers: RECQL4/FAM13C Genes Address Common Hub Genes and Drugs
    (Galenos Publ House, 2025-01-02) Duran, Gizem Ayna; Duran, Assist. Prof. Dr. Gizem Ayna
    Objective: The prevalence of breast cancer and gynaecological cancers is high, and these cancer types can occur consecutively as secondary cancers. The aim of our study is to determine the genes commonly expressed in these cancers and to identify the common hub genes and drug components. Materials and Methods: Gene intensity values of breast cancer, gynaecological cancers such as cervical, ovarian and endometrial cancers were used from the Gene Expression Omnibus database Affymetrix Human Genome U133 Plus 2.0 Array project. Using the linear modelling method included in the R LIMMA package, genes that differ between healthy individuals and cancer patients were identified. Hub genes were determined using cytoHubba in Cytoscape program. “ShinyGo 0.80” tool was used to determine the disease-specific biological KEGG pathways. Drug.MATADOR from the ShinyGo 0.80 tool was used to predict drug-target relationships. Results: The RecQ Like Helicase 4 and Family with Sequence Similarity 13 Member C genes were found to be similarly expressed in breast cancer and gynaecological cancers. Upon KEGG pathway analyses with hub genes, Drug.MATADOR analysis with hub genes related to cancer related pathways was performed. We have determined these gene/drug interactions: NBN (targeted by Hydroxyurea), EP300 (targeted by Acetylcarnitine) and MAPK14 (targeted by Salicylate and Dibutyryl cyclic AMP). Conclusion: The drugs associated with hub genes determined in our study are not routinely used in cancer treatment. Our study offers the opportunity to identify the target genes of drugs used in breast and gynaecological cancers with the drug repurposing approach.
  • Thumbnail Image
    Article
    Pan-Cancer Analyses Identify the Rrm2 Gene as a Biomarker With Diagnostic and Prognostic Roles in Multiple Human Cancers Via Interactions With the Hsa-Let Mirna and Ezh2
    (Biolife Sas, 2023-11-20) Ayna Duran, Gizem; Duran, Gizem Ayna
    Background: Pan-cancer research has recently been conducted to identify genomic differences in multiple cancers compared with those in normal tissues. Our aims were to determine common differentially expressed genes (DEGs) by analysing the genomes of multiple cancers and to identify common cancer biomarkers for both diagnosis and treatment by determining the effect of these commonly changed genes on survival.Methods: We performed DEG and survival analyses by considering differences in expression levels in tumour and related normal tissues using the R programme and bioinformatic webtools Gene Expression Profiling Interactive Analysis 2 (GEPIA2), UALCAN, TIMER2.0, KM-plot, ShinyGO 0.77, miRTargetLink, and CancerMIRNome.Results: In our study, 5 genes (ribonucleotide reductase regulatory subunit M2 (RRM2), enhancer of the zeste homolog 2 (EZH2), Proliferating cell nuclear antigen (PCNA) clamp associated factor (PCLAF), mitotic checkpoint serine/threonine kinase B (BUB1B), and centromere protein U (CENP-U)) were found to be upregulated in multiple cancers. Among these genes, the RRM2 gene was upregulated in more cancers and datasets. According to the gene enrichment analysis, the EZH2 gene also acted together with the RRM2 gene in terms of biological significance. Furthermore, instead of finding chemical agents that would inhibit the overexpression of both the RRM2 and EZH2 genes, miRNA screening targeting both genes were performed. As a result, hsa-let-7a-5p miRNA was found to have a strong interaction with both genes through the p53-and cell cycle-dependent pathways.Conclusion: The commonly upregulated RRM2 and EZH2 genes can be utilised as biomarkers for early diagnosis of multiple cancers. The joint interactions of the RRM2 and EZH2 genes with hsa-let-7a-5p may be a promising early treatment by inhibiting the expression levels of both genes by targeting hsa-let-7a-5p, an miRNA with low expression levels in cancers.
  • Thumbnail Image
    Conference Object